Epigenetics of functional hypothalamic amenorrhea

L. Fontana, E. Garzia, G. Marfìa, V. Galiano and M. Miozzo

Functional hypothalamic amenorrhea (FHA) is a temporary infertility characterized by the suppression of the hypothalamic–pituitary–gonadal (HPG) axis, induced by the inhibition of the hypothalamic pulsatile secretion of the gonadotropin-releasing hormone (GnRH), in the presence of stressors, including eating disorders, excessive exercise, and psychological distress. Although the stressful factors that may lead to FHA are well-established, little is known about the inter-individual variability in response to stress and the consequent inhibition of the HPG axis. Not all women, indeed, manifest FHA in presence of stressful conditions. Recent studies highlighted a genetic contribution to FHA. Rare or polymorphic variants in genes that control the development and/or function of GnRH neurons may contribute, indeed, to the adaptability of the reproductive axis to stress factors. Also epigenetic changes have been associated with different pathways involved in the HPG axis and therefore, take part in FHA and confer a personal predisposition to anovulation consequent to a stressful event, or represent biological markers of response to stress. This review summarizes recent advances in the identification of the contribution of (epi)genetics to FHA and to long-term complications of functional amenorrhea, and reports insights into the involvement of additional genetic loci in FHA development on the bases of the clinical and molecular overlap with other gynecological and/or psychological conditions. Finally, we describe the promising application of induced pluripotent stem cells (iPSCs) as a new approach to investigate the molecular pathways involved in FHA.

KEYWORDS
functional hypothalamic amenorrhea (FHA), epigenetics, susceptibility genes, anorexia nervosa, delayed puberty
Introduction

Functional hypothalamic amenorrhea (FHA) may be considered a natural protective mechanism in women against stressful events, that temporarily suppress reproductive functions when physical conditions are not suitable to sustain a pregnancy. FHA is characterized by the suppression of the hypothalamic–pituitary–gonadal (HPG) axis, induced by the inhibition of the hypothalamic pulsatile secretion of the gonadotropin-releasing hormone (GnRH), in the presence of stressors, including eating disorders, excessive exercise, and psychological distress. FHA thus delineates as a temporary infertility characterized by the absence of menses for at least 3–6 consecutive months in absence of pregnancy, hyperandrogenism, hyperprolactinemia or other endocrine dysfunctions.

Although the stressful factors that may lead to FHA are well-established, little is known about the inter-individual variability in response to stress and the consequent inhibition of the HPG axis. Studies in women identified a high variability in the occurrence of FHA after heavy training. In particular, the frequency of FHA in athletes ranges from 6 to 43% (1); while in non-athletes, following the same training scheme of athletes, the frequency of FHA has been reported to be higher, with only about 14% of women with regular menstrual cycles during the training (2). Studies in nonhuman primates also confirmed the variable response of the HPG to stress (3–5). Like women, female macaques exposed to a combination of stresses showed different degrees of anovulation. Some animals, considered stress-sensitive, have an immediate suppression of ovulation and menstrual cycles, whereas others are highly stress-resilient and never experience FHA in presence of stress (3). Immunohistochemistry analysis of hypothalamic sections from resilient and stress-sensitive monkeys highlighted a higher GnRH expression in the neuron soma and lower GnRH levels in the neuron fibers of stress-sensitive animals, suggesting differences in the neuronal mechanisms involved in GnRH synthesis, transport and release in stress-sensitive compared with resilient animals (5).

Taken together, these studies suggest that the genetic variability in genes that control the development and/or function of GnRH neurons may contribute to the adaptability of the reproductive axis to a stressful condition. This hypothesis is confirmed by recent studies that highlighted the presence of a higher frequency of rare variants in genes associated with idiopathic hypogonadotropic hypogonadism (IHH) in women with FHA compared to women with regular menses (6, 7). The identification of other pathways, comprising those involving ghrelin and leptin that control the HPG axis as endocrine mediators of energy balance, could suggest the classification of FHA as a multifactorial and complex condition.

In addition to the presence of rare variants and polymorphisms that may alter the regulation of the axis, epigenetic changes could be associated with different pathways involved in the HPG axis (8, 9) and therefore, take part in FHA and confer a personal predisposition to anovulation consequent to a stressful event, or represent biological markers of response to stress.

In this review we summarize recent advances in the identification of the contribution of (epi)genetics to FHA and to long-term complications of functional amenorrhea, and reports insights into the involvement of additional genetic loci in FHA development on the bases of the clinical and molecular overlap with other gynecological and/or psychological conditions. Finally, we describe the promising application of induced pluripotent stem cells (iPSCs) as a new approach to investigate the molecular pathways involved in FHA.

Genetics and molecular overlapping between FHA and IHH

The clinical overlapping between FHA and IHH prompted the hypothesis that mutations in genes involved in IHH may confer susceptibility to the functional deficiency of GnRH secretion, the hallmark of FHA. IHH is, indeed, characterized by the failure to activate the pulsatile secretion of GnRH or the defective action of GnRH at pituitary level, thus resulting in absence of puberty and infertility. IHH is classified in IHH associated to anosmia, also known as Kallman syndrome (KS), a mendelian condition characterized by locus heterogeneity, that is found in about the 60% of IHH patients (10, 11); and normosmic IHH (nIHH) observed in the remaining patients.

The presence of total or partial loss of olfaction is caused by the common embryonic origin and developmental pathways of GnRH and olfactory neurons. Similar to olfactory fibers, GnRH neurons originate in the nasal placode from where they migrate to the hypothalamus (12). This common developmental pathway accounts for the defective migration of both GnRH and olfactory neurons in KS. The identification of the underlying molecular mechanism causative of KS, and the genetic characterization of affected families, allowed the identification of mutations in genes involved in the migration of GnRH and olfactory neurons, such as KAL1 and FGFR1 (13). More recently, mutations in the PROK2 and PROK2 genes, that encode for a G-coupled receptor and its ligand with a fundamental role in the development of GnRH neuronal progenitors, have also been associated to IHH (14). Other genes that are involved in the development of IHH include: i) CHD7, encoding for a chromodomain protein associated to the CHARGE syndrome, suggesting a link between IHH, chromatin remodeling and transcription regulation; ii) KISS1 and KISS1R, that encode for...
kisspeptin 1 and its endogenous receptor, that are the most potent regulators of GnRH secretion in humans; iii) *LEP*, that encodes for leptin, a fat-released hormone that regulates food intake, energy expenditure and fertility at the hypothalamic level, and its receptor LEPR, thus linking body weight with the reproductive capability; iv) *TAC3* and *TAC3R*, that encode for neurokinin B and its receptor, suggested to have a role in GnRH secretion; v) *PCSK1*, encoding for the neuroendocrine convertase 1 (NEC1), which converts inactive peptides to bioactive molecules, including the adrenocorticotropic hormone (ACTH); and vi) *GNRHR*, that is the main regulator of GnRH secretion.

**Rare variants in IHH-related genes in FHA**

After the identification of FHA in some families with KS/nIHH, Caronia and colleagues found six pathogenic variants in genes associated with IHH development in patients with FHA (Table 1 and Figure 1), thus suggesting, for the first time, an involvement of rare variants in these loci in the predisposition to FHA in presence of stressful situations (6). The study included 55 women with FHA and highlighted six heterozygous variants in *FGFR1*, *PROKR2*, *GNRHR* and *KAL1* in 7 patients with FHA and at least one predisposing factor to secondary amenorrhea. Four of these patients also reported a family history of FHA, but the genetic analysis was not extended to other affected relatives to confirm the association. The observed variants were considered pathogenic, since they all were located in conserved aminoacidic residues and induced a significant loss of function (6). None of these mutations were observed in a group of 422 control women, some of them also exposed to one risk factor for FHA (i.e., training for more than 5 hours a week). In addition, one mutation in the *PROKR2* gene (L173R) and in *GNRHR* were also detected in a cohort of 160 IHH patients.

The same authors further deepened the role of genetics in FHA, extending the mutational analysis to 53 genes involved in IHH and the number of FHA patients included in the study (7). This mutational screening allowed the identification of 78 heterozygous variants in 58 out of 108 women with FHA (Table 1 and Figure 1). Among these, three variants were validations of the previously smaller cohort. 32 novel variants were identified in patients resulted negative at the previously sequencing analysis, and two were detected in a patient with a previously identified mutation in the *ANOS1* gene. Most of these variants were observed in FHA women only, while few of them were also found in control women, thus excluding a pathogenetic role of these variants per se in the development of FHA. However, the frequency of rare variants in GnRH-related genes was higher in FHA patients compared to controls, and 35% of variants observed in amenorrheic women has been previously associated with IHH development, compared to 19% found in the control group (7). In addition, FHA women harbor a higher number of variants (three or more) compared to the control group. In this latter many participants did not show any variant. In this study, no associations with the number of FHA risk factors nor with the family history for the condition were observed (7).

Overall, this evidence further supports the involvement of genetic variants in the variable response of the reproductive axis to stress. Moreover, since only mutations in *FGFR1* and *CHD7* are known to be associated to IHH with a dominant inheritance, the authors hypothesized that the GnRH deficiency may be considered as a semi-dominant disease, with heterozygous carriers that show a milder phenotype, characterized by FHA only in presence of triggering external factors, while patients with biallelic or di/oligogenic mutations show a severe form of GnRH deficiency resulting in IHH. This is supported by the identification of some rare variants also in eumenorrheic women. These studies thus suggest, for the first time, that FHA may be part of a disease spectrum with a genetic base.

**Genetic and molecular overlapping between FHA and other gynecological disorders**

Several other disorders, including delayed puberty and anorexia nervosa, share with FHA a partially overlapping clinical presentation and the causative molecular mechanisms, suggesting a common genetic base or predisposition. This common picture stems from both the central role of the hypothalamus, which controls most of the basic functions that are interconnected, and the multifunctional role of the hormones released by the hypothalamus. In particular, genetic variants in genes involved in pathways controlling appetite or stress-response might also contribute to FHA. Anorexia nervosa (AN), for example, is a multifactorial eating disorder characterized by a chronic energy deficiency that leads to the suppression of the HPG axis because of the reduced secretion of GnRH, as observed in FHA. AN and FHA enter in differential diagnosis since AN may be considered a cause of functional amenorrhea. Differently from FHA, AN shows a strong heritability since 1) family studies have demonstrated a significant prevalence of AN in first-degree relatives of probands compared to controls, with a 11.3 times more probability of relatives to develop AN compared to controls (15, 16); 2) studies on twins highlighted that monzygotic twins have a higher concordance rate of AN development compared to dizygotic twin, with an estimated heritability of 88%; 3) population studies reported an estimated heritability of approximately 58% for AN, with the remaining variance associate with environmental factors (17); 4) mutational screenings and genome-wide association studies have
| Gene     | Protein activity                  | Role in HPG axis                          | Variants                              |
|----------|-----------------------------------|------------------------------------------|---------------------------------------|
| FGFR1    | Tyrosine kinase receptor          | GnRH neuron migration/development        | Arg756His, Gly260Glu                  |
| PROKR2   | GPCR                              | GnRH neuron migration/development        | Arg85His, Leu173Arg, Thr340Ser, Met111Arg |
| GNRHR    | GPCR                              | GnRH action                              | Arg262Gln, Ser168Agr, Gln106Arg       |
| KAL1     | Cell adhesion                     | GnRH neuron migration/development        | Val371Ile                             |
| RAB3GAP2 | Neurotransmitter exocytosis       | Neurodevelopmental syndrome with IHH*     | Asp1206Tyr, Pro527Leu, Arg420Cys, Leu133Ile |
| RAB3GAP1 | Neurotransmitter exocytosis       | GnRH neuron migration/development        | Arg336Cys, Arg954His                  |
| HESX1    | Transcriptional repressor         | Pituitary gland development              | Val129Ile                             |
| SOX2     | Transcription factor              | Pituitary gland development              | Gly22Ser                              |
| KLB      | Membrane receptor                 | GnRH neuron migration/development        | Ala169Thr, Gly908Val, Lys141Glu, Val104Ile, Cys290Tyr |
| TACR3    | TAC3 receptor                     | GnRH secretion                           | His248Arg, Pro933Arg, Leu110Asp*625 |
| OTUD4    | De-ubiquitylating enzyme          | Neurodevelopmental syndrome with IHH*     | Pro2171Ser, Asn153Ser, Asp580Asn      |
| SRA1     | Regulator of nuclear receptors    | Steroid activity                         | Ser241Tyr, Gly92Val                  |
| SPRY4    | Inhibitor of MAPK receptor        | GnRH neuron migration/development        | Cys248Arg, Gly291Glu, Ser244Arg, Arg459Cys, Asp728His, Pro1705Gln, Arg1942Tyr, Met2527Leu, Met396Ile, Ser466Leu, Leu2984Phe, Met340Val |
| PROP1    | Transcription factor              | Pituitary gland development              | Ala142Val, Pro171Ser, Asp580Asn      |
| SEMA4E   | Growth factor                     | GnRH neuron migration/development        | Gly317Ser, Arg315Pro, Arg353Pro      |
| GNRH1    | Gonadotropin-releasing hormone    | GnRH secretion                           | Ile48Arg, Gly291Glu, Ser244Arg, Arg459Cys, Asp728His, Pro1705Gln, Arg1942Tyr, Met2527Leu, Met396Ile, Ser466Leu, Leu2984Phe, Met340Val |
| FGFR1    | Growth-factor receptor            | GnRH neuron migration/development        | Gly291Glu, Ser244Arg, Arg459Cys, Asp728His, Pro1705Gln, Arg1942Tyr, Met2527Leu, Met396Ile, Ser466Leu, Leu2984Phe, Met340Val |
| CHD7     | Chromatin-remodeling factor       | GnRH neuron migration/development        | Gly317Ser, Arg315Pro, Arg353Pro      |
| LHX3     | Transcription factor              | Pituitary gland development              | Gly317Ser, Arg315Pro, Arg353Pro      |
| WDR11    | Transcription factor              | GnRH neuron migration/development        | Val68Met                              |
| POLR3B   | Subunit of RNA polymerase III     | Neurodevelopmental syndrome with IHH*     | Lys721*                               |

(Continued)
highlighted several genetic loci that may account for the predisposition to AN (18). Common variants in neurotrophin signaling genes, including BDNF, NTRK2 and NTRK3, seem to contribute to the susceptibility to eating disorders (19, 20) (Table 2). Other signaling pathways, involving a cross-regulation of satiety and estrogen production, including the serotoninergic and leptin pathways, have been linked to an increased risk to develop AN. Common variants in the OPRD1, HTRD1, EB1 and SLCEA4 genes show a higher frequency in AN patients compared to controls and segregate in family members with AN, supporting their involvement in the etiology of AN (21–24) (Table 2). Common or rare variants in genes involved in these pathways have never been investigated in FHA patients. However, given the close link between FHA and AN, in addition to the evidence that food restriction is one of the main risk factors for FHA development, it can be hypothesized that variants in genes involved in satiety, appetite and weight regulation may play a role in the differential response to physical and/or psychological stressors and the consequent inhibition of the HPG axis in FHA.

Delayed puberty may occur in patients with FHA and IHH and can be considered an early clinical sign of these conditions. About two-third of FHA patients report a family history of delayed puberty with an apparent autosomal dominant pattern of inheritance, sometimes with incomplete penetrance (25, 26). Genome-wide association studies highlighted an association with genes involved in IHH, including LEPR, GNRH1 and TACR2 (27, 28) (Table 2). Besides, genetic screenings in IHH families identified mutations in HS6ST1, FGFR1 and KLB in IHH patients and their relatives manifesting delayed puberty only (29–31) (Table 2). Pathogenic mutations in the IGSF10 gene were also found in six unrelated families with delayed puberty in a large Finnish cohort of patients (32) (Table 2). IGSF10 mutations affect the migration of GnRH neurons from the vomeronasal organ in the nose to the forebrain during embryonic development, possibly affecting the predisposition to FHA as observed for other genes in the same pathway.

All this evidence supports a common genetic basis of FHA with AN, delayed puberty and IHH, strengthening, again, the hypothesis that monoallelic mutations in a subset of genes that modulate the HPG axis may lead to AN, delayed puberty and/or FHA, while biallelic mutations or a specific combination of heterozygous variants in these genes could lead to a more severe phenotype, including IHH or KS (33).
FIGURE 1
Schematic representation of the HPG axis regulation and the FHA predisposing genes. GnRH neurons in the hypothalamus release GnRH upon different stimuli: kisspeptin, produced by a specific group of hypothalamic neurons, is a major player in the neuroendocrine control of GnRH and gonadotrophins secretion; ghrelin and leptin allow the regulation of GnRH secretion according to energy balance (link between HPG axis and food intake); cortisol inhibits GnRH secretion (link between HPG axis and anxiety). FHA-predisposing genes are listed in the light blue boxes (created with BioRender.com).

TABLE 2 Predisposing genes to gynecological and psychological conditions showing overlapping features with FHA, and to long-term consequences of FHA.

| Disorder                  | Condition Description                                                                 | Overlapping with FHA                                                                 | Affected pathway                                                                 | Genes involved                          |
|---------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------|
| Gynecological disorders   | Anorexia nervosa                                                                       | AN is a chronic energy deficiency that leads to the suppression of the HPG axis because of the reduced secretion of GnRH | Neurotrophin signaling pathway Serotoninergic and leptin pathways                 | BDNF NTRK2 NTRK3 OPRD1 HTRD1 EBF1 SLC6A4 |
|                           | Delayed puberty                                                                        | Delayed puberty may occur in patients with FHA and can be considered an early clinical sign of this condition | IHH development                                                                  | LEPFR GNRH TACR2 Hs6ST1 FGFR1 KLBA       |
| Psychological disorders   | Anxiety                                                                                | The neuroendocrine response to stress and stress-related neuronal plasticity involves the HPG axis | Energy balance and anxiogenic effect of CRH                                      | IGSF10                                  |
|                           | Mood disorders                                                                         | Altered neuroplasticity related to stress                                             | Neuroplasticity, neurogenesis, neuronal survival, and differentiation            | BDNF NPY                                |
| Long-term consequences    | Osteopenia and osteoporosis                                                             | Prolonged hypoestrogenism in FHA leads to osteopenia and osteoporosis                 | Estrogen receptor                                                                | ESR1-Xba1                                |
|                           |                                                                                       |                                                                                      | Vitamin D receptor                                                              | VDRB3ml site                            |
|                           |                                                                                       |                                                                                      |                                                                                | VDRFokI site                            |
Genetic and molecular overlapping between FHA and psychological disorders

FHA may be considered a multifactorial disease with genetic factors and pathomechanisms overlapping not only with other gynecological conditions, but also with psychiatric traits, since an anxious behavior is considered a main sign of FHA. The hyperactivation of the hypothalamic–pituitary–adrenal (HPA) axis in presence of stressing factors is, indeed, a typical feature of FHA and this is believed to be one of the most important pathogenetic factors in FHA patients (34, 35). Increased corticotropin-releasing hormone (CRH) secretion results in an augmented secretion of adrenocorticotrophin from the pituitary, and cortisol from the adrenal glands that, in turn, leads to reduced GnRH secretion.

Several studies have highlighted a strong genetic component in anxiety predisposition or resilience to stress. Genome-wide association studies identified several common genetic variants in genes involved in the neuroendocrine response to stress and in neuronal plasticity that affect stress perception and increase the risk of developing stress-related disorders. Some of these polymorphisms are in genes playing a role also in controlling the HPG axis, thus suggesting a possible link among stress-associated genetic variants, FHA, and anxiety. In particular, specific polymorphisms (i.e. rs16147 and rs3214187) in the Neuropeptide Y, which acts as a regulator of energy balance and counteracts the anxiogenic effect of CRH (36) (Table 2), have been associated to a resilience or a stress-sensitive phenotype in presence of a stressful condition (37, 38). The NPY also controls GnRH concentration, by inducing its release in presence of adequate levels of estradiol. In hypoestrogenic women, NPY inhibits GnRH release and amenorrheic patients show lower levels of basal serum NPY (39, 40). NPY may, thus, act as a link between the HPG and HPA axis, and common or rare variants in the NPY gene may affect the HPG axis response to stress (Figure 2).

Neuroplasticity has a primary role in the predisposition to stress-related disorders. According to the neurotrophic hypothesis, mood-disorders may be associated with impaired structural plasticity and cellular resilience, with a key role of the brain derived neurotrophic factor (BDNF), that is highly expressed in the hippocampus and involved in neuroplasticity, neurogenesis, neuronal survival, and differentiation (41). Several

![Image](https://example.com/image.png)
studies have highlighted an increase of BDNF serum levels associated with stress and mood disorders (42). Genome-wide association studies pointed for the involvement of the Val66Met (rs6265) in anxiety and response to stress, with Val/Val homozygotes that show increased anxiety (43), suggesting a role of BDNF in gene-environment interactions (Table 2). Despite the function of BDNF in FHA is not fully understood, a significant lower concentration of plasma BDNF was found in FHA patients in comparison to healthy controls (44), possibly suggesting the contribution of BDNF in the altered stress response associated to FHA (Figure 2), paving the way for the analysis of common variants in the BDNF gene that may account for the anxiogenic phenotype of FHA women.

**Genetic predisposition to long-term complications of FHA**

FHA is a complex clinical condition, that should be addressed with a multidisciplinary approach. The close interconnections between the hormonal and neuroendocrine status to regulate homeostasis, lead, consequently, to clinical manifestations other than amenorrhea in FHA women. The final endocrinological consequence of GnRH impairment is, indeed, hypoestrogenism. Persistent low levels of estrogen have negative effects on different aspects of female health. In particular, normal estrogen levels are fundamental in young women for bone metabolism, the correct function of the cardiovascular system, and for mental health. Considering these pleiotropic effects of hypoestrogenism, genetic studies on amenorrheic patients should also include the genotyping of candidate loci associated with long-term complications of FHA.

Among these, prolonged hypoestrogenism in young women with FHA is associated with osteopenia and osteoporosis. Studies in women with AN highlighted the association of specific polymorphisms with bone mineral density (BMD). In particular, the A allele at a polymorphic site of the estrogen receptor alpha ESRI-XbaI (rs934079) has been associated with a reduced BMD (45) (Table 2); while the AA genotype at the VDRBsm1 site (rs1544410) and the CT genotype at the VDRFokI site (rs228570) of the vitamin D receptor (VDR), both show a positive correlation with BMD in patients with AN (46) (Table 2). According to this evidence, the identification of FHA women at higher risk for reduced BMD should be mandatory for a timely treatment and to avoid long-term consequences of FHA. Polymorphic variants in ESR receptors may also be investigated in association to other FHA-related health consequences, including cardiovascular disorders primarily derived from endothelial dysfunction secondary to hypoestrogenism (47) (Figure 2).

Serum sex steroid levels in women also control mood. Low levels of estrogen in FHA women are strongly coupled to the modulation of the activity of different neuropeptides and neurotransmitters, in particular serotonin and dopamine, affecting mood in amenorrheic patients (48).

Mood disorders and anxiety are both causes and effects of FHA, thus establishing a negative loop that exacerbates the effects of mood disorders and sustains FHA. As previously described, many variants have been identified in genes associated with a personal response to stress and estrogen sensitivity that influence mood disorder predisposition. The identification of genetic variants in these or other genes in the same pathways may allow the identification of FHA patients who are more predisposed to mood disorders. This approach could improve a tailored therapeutic approach based on targeted therapies to avoid or disrupt the loop between FHA and mood disorders.

**The epigenetic contribution to FHA**

Epigenetic mechanisms govern gene expression without changing gene sequence and comprise chromatin changes, DNA methylation, and the expression of non-coding RNAs. The epigenetic signatures can be modified in response to environmental factors, stress, or disease, and mediate the response of the organism to external factors. Importantly, they can be reverted by epigenetic drugs, as demonstrated in cancer, by changes in behavioral habits or non-pharmacological treatments, such as psychotherapy.

Recent evidence highlighted the importance of the epigenetic regulation of GnRH expression by a network of miRNAs, epigenetic modifications, and transcription factors, suggesting an important role of these mechanisms in regulating the HPG axis and, therefore, their possible involvement in FHA. The tight interplay between genes and environment in FHA development and the identification of a few genetic variants associated to FHA predisposition, suggest that epigenetic factors may represent additional candidates underlying FHA pathogenesis. Recent studies on mice have reported a pivotal role of epigenetics in controlling GnRH neuron ontogenesis, through the coordinated actions of Dnmt3b, Tet1 and Ezh2 on the Fgf8 transcription (49). Moreover, in vitro studies further highlighted that the GnRH gene responds to external stimuli by modulating chromatin modifications also in mature GnRH neurons (50). This evidence suggests that epigenetics is a major molecular regulator of GnRH neuron development and function, and that the deregulation of these mechanisms may affect the activity of the HPG axis and the reproductive capacity.

Several studies analyzed the epigenetic profiling in amenorrheic women, mainly with AN, thus highlighting
s several differentially methylated genes. In particular, LEP and LEPR methylation levels were lower in AN women compared to controls (51) (Figure 2). Besides, lower DNA methylation of the LEP gene was associated with a significant hypermethylation during psychotherapeutic treatment and full recovery in AN patients (51), thus suggesting a predictive value of LEP methylation in identifying patients with a higher probability of recovery after treatment (51). Also hypomethylation of the GHS-R1A gene, that encodes for the ghrelin receptor, has been reported in AN patients, supporting the effect of environment on satiety and ghrelin resistance (52), and a possible effect of this epigenetic alterations in FHA patients (Figure 2).

GnRH secretion is controlled also by the activity of specific transcription factors. In particular, EAP1 (Enhanced At Puberty 1) is a transcription factor with a dual activity on the GnRH gene: it activates GnRH transcription and, at the same time, inhibits the expression of the preproenkephalin, that represses GnRH secretion. A polymorphic site in the 5-UTR of the gene has been associated with a higher risk for amenorrhea in non-human primate models (53), thus linking the epigenetic control of GnRH with common genetic variants that confer a higher risk for FHA (Figure 2).

Recently, growing findings have unveiled the central position of miRNAs as key regulators of GnRH secretion and consequent pituitary activation. Some miRNAs (miR-132, miR-212, miR-361-3p) have been reported to be induced by GnRH (54, 55) and play a role in the gonadotropin pathways, by directly targeting the 3'-UTR of LH and FSH transcripts or downregulating the expression of specific transcription factors (56) (Figure 2). The expression profiling of miRNAs in peripheral blood is emerging as a promising tool to monitor the effect of hormonal therapy in FHA. Studies on animal models have, indeed, demonstrated that kisspeptin-based hormonal therapy stimulates gonadotropin secretion and the altered expression of specific miRNAs in plasma (57). In silico prediction of targeted transcripts highlighted that kisspeptin-induced miRNAs may affect cell transport, structural and functional cell polarity, neural networks and intracellular trafficking, in addition to DNA methylation and sphingolipid metabolism. These studies, thus, open new research venues to identify the involvement of miRNAs in FHA and their possible use as peripheral biomarkers to monitor the effect of therapies. Nonetheless, microRNAs are not in clinical use yet, mainly due to technological limitations, including the lack of assay standardization and reproducibility (58).

iPSCs to study the molecular mechanisms underlying amenorrhea

Most studies focused on the dissection of the neuroendocrine mechanisms leading to GnRH inhibition and FHA in presence of stress have been performed on animal models (5, 59, 60). However, this approach cannot fully recapitulate the complexity of the disease, given the physiological differences in estrous and menstrual cycles, the failure of reproduce in animal stressful conditions comparable to humans, and the higher complexity of response to stress in human that also encompasses self-awareness. In addition, since FHA is a multifactorial disease, animal models do not allow the comprehensive investigation of (epi)genetic and environmental factors associated with FHA. For these reasons, induced pluripotent stem cells (iPSCs) from FHA patients, that can be differentiated into GnRH neurons, are a promising tool to deepen the molecular bases of FHA, and in vitro investigate the effect of predicted predisposing variants and new therapeutic strategies.

In the last years, the generation of iPSC lines combined with the CRISPR–Cas9 technology has led to the generation and characterization of GnRH neurons, that are promising cell models to dissect signaling pathways and gene regulatory networks involved in human GnRH neuron development and function (61, 62). iPSCs from patients with AN have been already used to study changes in gene expression profiles that may occur in AN, highlighting that most of differentially expressed genes belong to the tachykinin receptor pathway and estrogen response (63), thus suggesting their possible application also to study the pathomechanisms underlying FHA. iPSCs may be also used to test therapies targeting not only GnRH release, but also the serotoninergic and dopaminergic neurotransmission, in order to improve the behavioral features of FHA, taking into account the personal response mediated by the epigenetic profile of each patient.

Conclusions

Recent evidence highlighted that the establishment of FHA is variable among women, because it is a complex disease whose phenotypic appearance is influenced by several factors, including stress, behavioral habits and (epi)genetics, that together impact on the regulation of the HPG axis.

For this reason, (epi)genetic variants possibly associated to the personal predisposition to FHA should be investigated...
among genes that control the release and function of HPGe-related hormones, and among genes involved in the interconnection between the environment and stress response.

The identification of rare genetic and epigenetic variants associated with FHA may have important clinical implications, as they may represent druggable targets for personalized medicine. In particular, germ-line variants may improve the clinical stratification of patients according to the patient-specific molecular profile, whereas epigenetic specific signatures, based on their dynamic nature, may represent valuable peripheral biomarkers for the diagnosis of the disease and for monitoring the effect of pharmacological and psychological therapies.

Author contributions

FL critically revised the literature and wrote the manuscript; GE, MG, and GV provided support for the clinical content of the manuscript and critically reviewed the revision; MM supervised and edited the manuscript. All authors contributed to the article and approved the submitted version.

References

1. Feicht CB, Johnson TS, Martin BJ, Sparks KE, Wagner WW. Secondary amenorrhea in athletes. Lancet (1978) 2(8650):1145–6. doi: 10.1016/S0140-6736(78)92294-8.
2. Bullen BA, Skirnis GS, Bertins IZ, von Mering G, Turnbull BA, McArthur JW. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med (1985) 312(21):1349–53. doi: 10.1056/NEJM198505233122103.
3. Bethea CL, Strezsher JM, Mirkes SL, Sanchez RL, Reddy AP, Cameron JL. Serotonin-related gene expression in female monkeys with individual sensitivity to stress. Neurosci (2005) 152(1):151–66. doi: 10.1016/nesience.2004.11.022.
4. Bethea CL, Phu K, Reddy AP, Cameron JL. The effect of short moderate stress on the midbrain corticotropin-releasing factor system in a macaque model of functional hypothalamic amenorrhea. J Steril (2013) 109(4):1111–21. doi: 10.1016/j.fertnstert.2013.05.052.
5. Centeno ML, Sanchez RL, Cameron JL, Bethea CL. Hypothalamic gonadotrophin-releasing hormone expression in female monkeys with different sensitivity to stress. J Neuroendocrinol (2007) 19(8):594–604. doi: 10.1111/j.1365-2826.2007.01566.x.
6. Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, Thambundit A, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med (2011) 364(3):215–25. doi: 10.1056/NEJMoa1011064.
7. Delaney A, Burkholler AR, Lavender CA, Plummer L, Mericq V, Merino PM, et al. Increased burden of rare sequence variants in GnRH-associated genes in women with hypothalamic amenorrhea. J Clin Endocrinol Metab (2011) 106(3):e1441–52. doi: 10.1210/denim/dqsa09.
8. Oyola MG, Handa RJ. Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes: sex differences in regulation of stress responsivity. Stress (2017) 20(3):476–94. doi: 10.1080/10253890.2017.1369523.
9. Manotas MC, González DM, Cepeños C, Forero C, Rojas Moreno AP. Genetic and epigenetic control of puberty. Sex Dev (2022) 16(1):1–10. doi: 10.1159/000519039.
10. Beate K, Joseph N, Nicolas de R, Wolfram K. Genetics of isolated hypogonadotropic hypogonadism: Role of GnRH receptor and other genes. Int J Endocrinol (2011) 2012:e147893. doi: 10.1155/2012/147893.
11. Cangiano B, Swee DS, Quinton R, Bonomi M. Genetics of congenital hypogonadotropic hypogonadism: peculiarities and phenotype of an oligogenic disease. Hum Genet (2021) 140(1):77–111. doi: 10.1007/s00439-020-02147-1.
12. Schwanzel-Fukuda M. Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Microsc Res Tech (1999) 44(3):2–10. doi: 10.1002/(SICI)1097-0299(19990101)44:1<2::AID-JEMT2>3.0.CO;2-4.
13. Albuisson J, Pécheux C, Carel JC, Lacombe D, Leheup B, Lapuzina P, et al. Kallmann syndrome: 14 novel mutations in KAL1 and FGR3 (KAL2). Hum Mutat (2005) 25(1):98–9. doi: 10.1002/humu.9298.
14. Prosser HM, Bradley A, Caldwell MA. Offactory bulb hypoplasia in Prox1 null mice stems from defective neuronal progenitor migration and differentiation. Eur J Neurosci (2007) 26(12):3339–44. doi: 10.1111/j.1460-9586.2007.05958.x.
15. Strober M, Morrell W, Burroughs J, Salkin B, Jacobs C. A controlled family study of anorexia nervosa. Psychiatr Res (1985) 19(2):239–46. doi: 10.1016/0022-3956(85)90022-9.
16. Wade TD, Bulik CM, Neale M, Kendler KS. Anorexia nervosa and major depression: shared genetic and environmental risk factors. Am J Psychiatry (2000) 157(3):469–71. doi: 10.1176/appi.ap.157.3.469.
17. Paolicchi I, Kiani AK, Manara E, Beccari T, Ceccherini MR, Stoppiglia L, et al. Genetic contributions to the etiology of anorexia nervosa: New perspectives in molecular diagnosis and treatment. Mol Genet Genomic Med (2020) 8(7):e1244. doi: 10.1002/mgge.1244.
18. Schwanzel-Fukuda M. Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Microsc Res Tech (1999) 44(3):2–10. doi: 10.1002/(SICI)1097-0299(19990101)44:1<2::AID-JEMT2>3.0.CO;2-4.
19. Schwanzel-Fukuda M. Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Microsc Res Tech (1999) 44(3):2–10. doi: 10.1002/(SICI)1097-0299(19990101)44:1<2::AID-JEMT2>3.0.CO;2-4.
20. Mercader JM, Saus E, Agüera Z, Bayés M, Boni C, Carreras A, et al. Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. Am J Psychiatry (2007) 164(7):1208–16. doi: 10.1176/appi.ap.164.7.1208.
21. Schwanzel-Fukuda M. Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Microsc Res Tech (1999) 44(3):2–10. doi: 10.1002/(SICI)1097-0299(19990101)44:1<2::AID-JEMT2>3.0.CO;2-4.
22. Mercader JM, Ribasés M, Gratacòs M, González JR, Bayés M, de Cid R, et al. Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav (2007) 6(8):706–16. doi: 10.1111/j.1601-183X.2007.00301.x.
23. Bergen AW, Yeager M, Welch R, Ganjei JK, Deep-Soboslay A, Haque K, et al. Candidate gene analysis of the price foundation anorexia nervosa affected relative pair dataset. Curr Drug Targets CNS Neurol Disord (2003) 2(1):41–51. doi: 10.2174/1568007033338760.

Acknowledgments

The authors acknowledge the University of Milan (through the APC initiative) for covering open access publication fees.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
22. Brown KMO, Buja SR, Mann ET, Campbell DA, Stubbs MJ, Blundell JE. Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa. *Biol Psychiatry* (2007) 61(3):367–73. doi: 10.1016/j.biopsych.2006.04.007

23. Li D, Chang X, Connolly JJ, Tian L, Liu Y, Bhoi J, et al. A genome-wide association study of anorexia nervosa suggests a risk locus implicated in dysregulated leptin signaling. *Sci Rep* (2017) 7(1):18347. doi: 10.1038/s41598-017-10676-8

24. Chen J, Kang Q, Jiang W, Fan J, Zhang M, Yu S, et al. The 5-HTTPLR confers susceptibility to anorexia nervosa in Han Chinese: evidence from a case-control and family-based study. *PloS One* (2015) 10(3):e0119378. doi: 10.1371/journal.pone.0119378

25. Howard SR, Dunkel L. The genetic basis of delayed puberty. *Neuroendocrinology* (2018) 106(3):283–91. doi: 10.15252/nen.2018.1002023

26. Wehkallampi K, Widen E, Laine T, Palotie A, Dunkel L. Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care. *J Clin Endocrinol Metab* (2008) 93(3):723–8. doi: 10.1210/jc.2007-1786

27. Farooqi IS, Wangensteen T, Collins S, Matsere G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leupin receptor. *N Engl J Med* (2007) 356(3):327–47. doi: 10.1056/NEJMoa063988

28. Silveira LFG, Trarbach EB, Latronico AC. Genetics basis for GnRH-dependent puberty/gender development in humans. *Mol Cell Endocrinol* (2010) 324(1–2):20–8. doi: 10.1016/j.mce.2010.02.023

29. Tornberg J, Sykotsis GP, Keeke K, Plummer I, Hoang X, Hall JE, et al. Heparin sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar sulphation, modifies expression of estrogen receptors in patients with idiopathic hypogonadotropohypogonadism. *Proc Natl Acad Sci U S A* (2011) 108(28):11524–9. doi: 10.1073/pnas.1102284108

30. Pitteloud N, Myeung A, Quinton R, Acierno J, Dwyer A, et al. Mutations in filoblast growth factor receptor 1 cause kallmann syndrome with a wide spectrum of reproductive phenotypes. *Mol Cell Endocrinol* (2006) 254–255:60–9. doi: 10.1016/j.mce.2006.04.021

31. Xu C, Messina A, Somm E, Mirauo H, Kinnumen T, Acierno J, et al., encoding β-Klotho, is mutated in patients with congenital hypogonadotrophic hypogonadism. *EMBO Mol Med* (2017) 9(10):1379–97. doi: 10.15252/emmm.201607376

32. Howard SR, Guasti L, Ruiz-Babot G, Mancini A, David A, Storr HL, et al. IGf5F10 mutations dysregulate gonadotropin-releasing hormone neuronal migration resulting in delayed puberty. *EMBO Mol Med* (2016) 8(6):626–42. doi: 10.15252/emmm.201608250

33. Pitteloud N, Quinton R, Pearce S, Rauvio T, Acierno J, Dwyer A, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropohypogonadism. *J Clin Invest* (2007) 117(2):457–63. doi: 10.1172/JCI29884

34. Mezcukalski B, Podgirnuna-Stopa A, Warenik-Szymankiewicz A, Genazzani AR. Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. *Gynecol Endocrinol* (2008) 24(1–4):4–11. doi: 10.1080/09513590.2008.1087351

35. Berga SL, Daniels TL, Giles DE. Women with functional hypothalamic amenorrhea but not other forms of anovulation display amplified cortisol concentrations. *Fertil Steril* (1997) 67(6):1024–30. doi: 10.1016/S0015-0282(97)01454-3

36. Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Senegalese sole. *Int J Mol Sci* (2013) 14(23):E9051. doi: 10.3390/ijms14239051

37. Gan Y, Chen Y, Han X, Yu NX, Wang L. Neuropeptide y gene x environment interaction predicts resilience and positive future focus. *Appl Psychol Health Well Being* (2011) 3(3):488–50. doi: 10.1111/apwh.12162

38. Van der Auwera S, Peyrot WJ, Milaneschi Y, Hertel J, Baune B, Breen G, et al. Effects of vitamin d and estrogen receptor polymorphisms on bone mineral density in adolescents with anorexia nervosa. *J Pediatr Endocrinol Metab* (2019) 32(12):1377–84. doi: 10.1515/jpep-2019-0240

39. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. *Am J Cardiol* (2006) 97(1):174–51. doi: 10.1016/j.jacc.2005.10.076

40. Kormos V, Gaszner B. Role of neuropeptides in anxiety, stress, and depression: from animals to humans. *Neuropeptides* (2013) 47(6):401–19. doi: 10.1016/j.jnpep.2013.10.014

41. Linskott ML, Chung WCJ. TET1 regulates fibroblast growth factor 8 transcription in gonadotropin releasing hormone neurons. *PloS One* (2019) 14(7):e0220530. doi: 10.1371/journal.pone.0220530

42. Íyver AK, Brayman MJ, Mellon PL. Dynamic chromatin modifications control GnRH gene expression during neuronal differentiation and protein kinase c signal transduction. *Mol Endocrinol* (2011) 25(3):460–70. doi: 10.1210/me.2010-0403

43. Neyazi A, Buchholz V, Burket A, Hillemacher T, de Zwaan M, Herzog W, et al. Association of leptin gene DNA methylation with diagnosis and treatment outcome of anorexia nervosa. *Front Psychiatry* (2019) 10:197. doi: 10.3389/fpsyt.2019.00197

44. Batury VL, Walton E, Tam F, Wronski ML, Buchholz V, Frielings E, et al. DNA Methylation of ghrelin and leptin receptors in underweight and recovered patients with anorexia nervosa. *J Psychiatr Res* (2020) 131:271–8. doi: 10.1016/j.jpsychires.2020.01.008

45. Oliveira CCV, Fatsini E, Fernande I, Anjos C, Chavogné F, Cárdia J, et al. Kisspeptin influences the reproductive axis and circulating levels of microRNAs in Senegalese sole. *Int J Mol Sci* (2020) 21(23):E9051. doi: 10.3390/ijms21239051

46. Precazzini F, Detassis S, Imperatori AS, Denti MA, Campomenosi P. Measurements methods for the development of MicroRNA-based tests for cancer diagnosis. *Int J Mol Sci* (2021) 22(3):1176. doi: 10.3390/ijms22031176

47. Lakan ME, Kremzien AA, Reid VL, Van Vugt DA. Developing a model of nutritional amenorrhea in rhesus monkeys. *Endocrinology* (2006) 147(1):483–92. doi: 10.1210/en.2005-0821

48. Matsumoto T, Nishihara M, Sato Y, Toda Y, Iwakura Y, Chida D. Functional hypothalamic amenorrhea due to increased CRH tone in melanocortin receptor 2-deficient mice. *Endocrinology* (2010) 151(11):5489–96. doi: 10.1210/en.2010-0687

49. Lund C, Ylitala P, Vuorio S, Balboa D, Trova S, Allert C, et al. Characterization of the human GalphaR neuronal developmental transcriptome using a GalphaR1+TDTomato reporter line in human pluripotent stem cells. *Dev Mol Mech* (2020) 13(3):dmm041035. doi: 10.1242/dmm.041035
62. Keen KL, Petersen AJ, Figueroa AG, Fordyce BI, Shin J, Yadav R, et al. Physiological characterization and transcriptomic properties of GnRH neurons derived from human stem cells. *Endocrinology* (2021) 162(9):bqab120. doi: 10.1210/endocr/bqab120

63. Negraes PD, Cugola FR, Herai RH, Trujillo CA, Cristino AS, Chailangkarn T, et al. Modeling anorexia nervosa: transcriptional insights from human iPSC-derived neurons. *Transl Psychiatry* (2017) 7(3):e1060. doi: 10.1038/tp.2017.37